ACXP
Acurx Pharmaceuticals, Inc.
$1.57
-4.85%
$6.7M
No data for this timeframe.
Vol
Market Cap$6.7M
Cap SizeNano Cap
Inst. Holders8 funds
Inst. Value$210.7K
Inst. Activity0 buys / 1 sells
Reddit Sentiment50° Neutral
SEC Reports4
Recent Activity
May 12, 2026
earnings_calendar
ACXP Q1 2026 Earnings Scheduled — 2026-05-12
May 4, 2026
SEC
Acurx Pharmaceuticals filed an S-1 to register 1,300,000 shares for resale by Lincoln Park Capital Fund, LLC under an ex
S-1 — Impact 5/10
May 4, 2026
SEC
Acurx Pharmaceuticals filed an S-1 to register 1,650,170 shares of common stock for resale by selling stockholders upon
S-1 — Impact 6/10
Apr 20, 2026
Insider
Shawah Robert G. was granted 25,900 shares
Chief Financial Officer
Apr 20, 2026
Insider
LUCI DAVID P was granted 37,100 shares
President and CEO
Apr 20, 2026
Insider
DELUCCIA ROBERT J was granted 37,100 shares
Director
Apr 16, 2026
SEC
Acurx Pharmaceuticals raised $2.5 million through a registered direct offering of common stock and pre-funded warrants,
8-K — Impact 5/10
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
17 shares ($42.00)
Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$17.00 (Sep 2025)
Current $1.57
Low $10.00
Median $10.00
High $31.00
3 analysts
$10.00
$31.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 19, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 13, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 10, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.43 ▲ +21.6% | $-0.45 — $-0.42 | 77% YoY | 2 |
| Next Q | $-0.46 ▲ +20.2% | $-0.48 — $-0.43 | 63% YoY | 2 |
| Current FY | $-1.97 ▲ +17.6% | $-2.00 — $-1.94 | 63% YoY | 2 |
| Next FY | $-2.13 ▲ +3.2% | $-2.50 — $-1.76 | -8% YoY | 2 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $115.4K | — |
| VANGUARD FIDUCIARY TRUST CO | $60.1K | — |
| MORGAN STANLEY | $24.1K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $8.5K | — |
| BARCLAYS PLC | $1.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 20, 2026 | Shawah Robert | A | $0.00 |
| Apr 20, 2026 | LUCI DAVID | A | $0.00 |
| Apr 20, 2026 | DELUCCIA ROBERT | A | $0.00 |
| Apr 20, 2026 | Scodari Joseph | A | $0.00 |
| Apr 20, 2026 | HARRISON THOMAS | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $210.7K total value (56,790 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, MORGAN.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 31,099 | $115.4K | 54.8% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 16,205 | $60.1K | 28.5% | — |
| 3 | MORGAN STANLEY | 6,500 | $24.1K | 11.4% | DOUBLED +129.9% |
| 4 | WELLS FARGO & COMPANY/MN | 2,300 | $8.5K | 4.0% | — |
| 5 | BARCLAYS PLC | 380 | $1.4K | 0.7% | — |
| 6 | GROUP ONE TRADING LLC | 245 | $909.00 | 0.4% | DOUBLED +1068.0% |
| 7 | BlackRock, Inc. | 60 | $223.00 | 0.1% | ADD +32.2% |
| 8 | CITIGROUP INC | 1 | $4.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 71 | 17 | -76.1% | $42.00 | 2025-Q4 |
| VANGUARD GROUP INC | TRIM | 529,349 | 145,537 | -72.5% | $74.4K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 26,600 | 87,781 | +230.0% | $44.8K | 2025-Q2 |
| UBS Group AG | DOUBLED | 47 | 38,759 | +82366.0% | $19.8K | 2025-Q2 |
| GROUP ONE TRADING LLC | DOUBLED | 1,165 | 13,607 | +1068.0% | $7.0K | 2025-Q2 |
| BlackRock, Inc. | ADD | 25,911 | 34,245 | +32.2% | $13.4K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 14,674 | 26,600 | +81.3% | $10.4K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 5,961 | 47 | -99.2% | $18.00 | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 46,201 | 106,201 | +129.9% | $86.4K | 2024-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 173 | 1,165 | +573.4% | $948.00 | 2024-Q4 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 5,222 | 173 | -96.7% | $329.00 | 2024-Q3 |
8 unique insiders with 8 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | Shawah Robert G. | Chief Financial Officer | AWARD | 25,900 | — | — |
| Apr 20, 2026 | LUCI DAVID P | President and CEO | AWARD | 37,100 | — | — |
| Apr 20, 2026 | DELUCCIA ROBERT J | Director | AWARD | 37,100 | — | — |
| Apr 20, 2026 | Scodari Joseph C | Director | AWARD | 2,150 | — | — |
| Apr 20, 2026 | HARRISON THOMAS L | Director | AWARD | 2,150 | — | — |
| Apr 20, 2026 | Donohue James J. | Director | AWARD | 2,150 | — | — |
| Apr 20, 2026 | DEAN JACK H | Director | AWARD | 2,150 | — | — |
| Apr 20, 2026 | Sailer Carl | Director | AWARD | 2,150 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
BEARISH
S-1
5/10
Acurx Pharmaceuticals filed an S-1 to register 1,300,000 shares for resale by Lincoln Park Capital F
May 4, 2026
BEARISH
S-1
6/10
Acurx Pharmaceuticals filed an S-1 to register 1,650,170 shares of common stock for resale by sellin
May 4, 2026
NEUTRAL
8-K
5/10
Acurx Pharmaceuticals raised $2.5 million through a registered direct offering of common stock and p
Apr 16, 2026
BEARISH
424B5
6/10
Acurx Pharmaceuticals is raising approximately $2.35 million through a registered direct offering of
Apr 16, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2025): 89% buy across 9 analysts — 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$17.00 mean target (Sep 2025)
$10.00 Low
$31.00 High
| Metric | Value |
|---|---|
| Current Price | $1.57 |
| Target Low | $10.00 |
| Target Mean | $17.00 |
| Target Median | $10.00 |
| Target High | $31.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.43 | $-0.45 | $-0.42 | 77.0% | +21.6% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.46 | $-0.48 | $-0.43 | 63.0% | +20.2% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-1.97 | $-2.00 | $-1.94 | 63.0% | +17.6% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-2.13 | $-2.50 | $-1.76 | -8.1% | +3.2% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.435 | |
| 7d ago | $-0.555 | +0.120 |
| 30d ago | $-0.555 | +0.120 |
| 60d ago | $-0.555 | +0.120 |
| 90d ago | $-0.670 | +0.235 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 19, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 10, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 10, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 19, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 15, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 15, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 13, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 15, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 11, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 17, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Dec 19, 2022 | HC Wainwright & Co. | INITIATE | — | Buy |
| Oct 20, 2022 | Alliance Global Partners | INITIATE | — | Buy |
| Nov 29, 2021 | Maxim Group | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 13, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 13, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$ACXP - Round #2? Sure looks like it!
▲ 1
💬 1
⚡ 0.5
May 12, 2026
earnings_calendar
ACXP Q1 2026 Earnings Scheduled — 2026-05-12
Mar 24, 2026
short_volume
Short Volume: ACXP — 56.7% short (0.3M / 0.6M)
Short: 321,122 | Exempt: 53,374 | TRF Vol: 566,400 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Mar 18, 2026
short_interest
FTD: ACXP — 106,959 shares ($0.5M) failed to deliver
Settlement: 20260318, Price: $4.88, FTD Value: $521,959.92, ACURX PHARMACEUTICALS INC COM
Mar 17, 2026
short_interest
FTD: ACXP — 112,131 shares ($0.5M) failed to deliver
Settlement: 20260317, Price: $4.81, FTD Value: $539,350.11, ACURX PHARMACEUTICALS INC COM
Mar 16, 2026
short_interest
FTD: ACXP — 289,531 shares ($1.1M) failed to deliver
Settlement: 20260316, Price: $3.88, FTD Value: $1,123,380.28, ACURX PHARMACEUTICALS INC COM
Mar 13, 2026
short_interest
FTD: ACXP — 378,365 shares ($1.9M) failed to deliver
Settlement: 20260313, Price: $5.01, FTD Value: $1,895,608.65, ACURX PHARMACEUTICALS INC COM
Mar 13, 2026
earnings_calendar
ACXP Q4 2025 Earnings After Market Close — 2026-03-13
Mar 12, 2026
short_interest
FTD: ACXP — 850,298 shares ($5.1M) failed to deliver
Settlement: 20260312, Price: $6.03, FTD Value: $5,127,296.94, ACURX PHARMACEUTICALS INC COM
Mar 11, 2026
short_interest
FTD: ACXP — 251,640 shares ($0.7M) failed to deliver
Settlement: 20260311, Price: $2.90, FTD Value: $729,756, ACURX PHARMACEUTICALS INC COM